CEO: Maria Fardis

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Key numbers

Market Capitalization:3634596300
Shares Outstanding: 126862000
Float: 117110499
Next Earning Date:2020-08-06
TTm EPS: -1.8371
TTm Dividend Rate:
200 days moving average:27.95
50 days moving average: 30.91
One day percent Change: 0.76

2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,